Semzuvolimab

Summary

Semzuvolimab (CHEMBL4297846) is a phase-3 clinical-stage antibody; indicated across 3 conditions including hiv infectious disease and autoimmune disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297846
Name	Semzuvolimab
Type	Antibody
Max phase	3

Also known as: Db4c7 mab, Mab db4c7, Semzuvolimab, Ub-421, UB-421, UB-421 (DB4C7 MAB), UB421, SEMZUVOLIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
HIV infectious disease	3	MONDO:0005109	EFO:0000180
autoimmune disease	2	MONDO:0007179	EFO:0005809

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04406727	PHASE3	NOT_YET_RECRUITING	UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
NCT03149211	PHASE3	WITHDRAWN	To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults
NCT04985890	PHASE2	NOT_YET_RECRUITING	A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
NCT01668043	PHASE2	COMPLETED	Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults
NCT02369146	PHASE2	COMPLETED	To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults
NCT03164447	PHASE2	UNKNOWN	UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
NCT04041362	PHASE2	WITHDRAWN	the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
NCT05056974	PHASE2	COMPLETED	A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
NCT05582694	PHASE2	WITHDRAWN	A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
NCT01140126	PHASE1	COMPLETED	Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults
NCT04620304	PHASE1	COMPLETED	Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).